{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-062031","form_type":"8-K","ticker":"NUVB","cik":"0001811063","company_name":"Nuvation Bio Inc.","filed_at":"2025-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.977272+00:00","generated_at":"2026-05-24T05:57:16.026498+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Nuvation Bio enters commercial supply agreement with Asymchem for taletrectinib drug product","bullets":["Asymchem will be non-exclusive supplier of taletrectinib drug product; Nuvation retains right to use alternate manufacturers.","Orders must be placed at least 180 days before delivery; cancellation subject to tiered fees.","Initial term is 5 years, auto-renews for consecutive 3-year terms unless non-renewed.","Company may terminate without cause on 30 days' notice; each party may terminate for material breach or insolvency."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-062031","json":"https://secwatch.observer/filing/0001193125-25-062031.json","markdown":"https://secwatch.observer/filing/0001193125-25-062031.md","text":"https://secwatch.observer/filing/0001193125-25-062031.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1811063/000119312525062031/0001193125-25-062031-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1811063/000119312525062031/d908716d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T05:57:16.026498+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}